- Datum24.02.2025
- Uhrzeit08:00 - 09:00 Uhr
- Veranstalter
XTB
Kein Moderator verfügbar
Kodiak Sciences Inc. Aktie
Verkaufen
Kaufen
Kodiak Sciences Inc. Chart
Kodiak Sciences Inc. Realtime-Kurs
| Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-6,33 %
Intraday
-15,40 %
1 Woche
-46,45 %
1 Monat
-55,28 %
Seit Jahresbeginn
-16,04 %
1 Jahr
-54,87 %
3 Jahre
-92,36 %
5 Jahre
Wikifolio
Passender Service zu Kodiak Sciences Inc.
Webinar zu Kodiak Sciences Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)2,185-11,600
- Jahrestief / Hoch ($)4,430-9,940
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Kodiak Sciences Inc.
Keine Dividenden verfügbar
Termine von Kodiak Sciences Inc.
Keine aktuellen Termine
Beschreibung
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
